FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2528418626> ?p ?o ?g. }

• W2528418626 endingPage "69" @default.
• W2528418626 startingPage "61" @default.
• W2528418626 abstract "•Atorvastatin for 20 weeks was studied in 98 individuals with suppressed HIV infection. •Atorvastatin did not decrease biomarkers of immune activation and inflammation. •Atorvastatin treatment resulted in robust reductions LDL-C, oxLDL, and LpPLA2. •Atorvastatin was well tolerated with no significant toxicity over 20 weeks. Background Persistent immune activation and inflammation in virologically suppressed human immunodeficiency virus (HIV) infection are linked to excess cardiovascular risk. Objective To evaluate atorvastatin as a strategy to reduce cardiovascular risk. Methods A5275 was a multicenter, prospective, randomized, double-blind, placebo-controlled, cross-over pilot study of atorvastatin (10 mg/day for 4 weeks then 20 mg/day for 16 weeks) with a planned enrollment of 97 HIV-infected participants ≥18 years old, receiving boosted protease inhibitor–based antiretroviral therapy for ≥6 months, with plasma HIV-1 RNAs below limits of quantification ≥180 days, and fasting low-density lipoprotein (LDL) cholesterol ≥70 and <130 mg/dL. Primary endpoints were differences of changes ([week 44–week 24]–[week 20–baseline]) in CD4+ and CD8+ T-lymphocyte activation (% CD38+/DR+) and plasma levels of IL-6 and D-dimer. Arms were compared using the Wilcoxon rank-sum tests and also summarized changes pre-to-post atorvastatin treatment. Analyses were as-treated. Results Ninety-eight participants were enrolled at 31 U S sites and 73 completed study treatment. Atorvastatin treatment did not decrease T-lymphocyte or monocyte activation, circulating biomarker levels (interleukin-6, D-dimer, soluble CD14, soluble CD163, monocyte chemoattractant protein-1, interferon-gamma–induced protein-10, high-sensitivity C-reactive protein, CD40L, and P-selectin) or white blood cell Krüppel-like Factor 2/4 messenger RNA levels. Pre-to-post atorvastatin reductions in calculated LDL (−38%), oxidized-LDL (−33%), and lipoprotein-associated phospholipase A2 (−31%) were significant (P < .01). Conclusion In virologically suppressed individuals with HIV infection, atorvastatin did not significantly decrease levels of soluble or cellular biomarkers of immune activation and inflammation but resulted in robust reductions in LDL cholesterol, oxLDL, and lipoprotein-associated phospholipase A2, biomarkers associated with cardiovascular risk. Persistent immune activation and inflammation in virologically suppressed human immunodeficiency virus (HIV) infection are linked to excess cardiovascular risk. To evaluate atorvastatin as a strategy to reduce cardiovascular risk. A5275 was a multicenter, prospective, randomized, double-blind, placebo-controlled, cross-over pilot study of atorvastatin (10 mg/day for 4 weeks then 20 mg/day for 16 weeks) with a planned enrollment of 97 HIV-infected participants ≥18 years old, receiving boosted protease inhibitor–based antiretroviral therapy for ≥6 months, with plasma HIV-1 RNAs below limits of quantification ≥180 days, and fasting low-density lipoprotein (LDL) cholesterol ≥70 and <130 mg/dL. Primary endpoints were differences of changes ([week 44–week 24]–[week 20–baseline]) in CD4+ and CD8+ T-lymphocyte activation (% CD38+/DR+) and plasma levels of IL-6 and D-dimer. Arms were compared using the Wilcoxon rank-sum tests and also summarized changes pre-to-post atorvastatin treatment. Analyses were as-treated. Ninety-eight participants were enrolled at 31 U S sites and 73 completed study treatment. Atorvastatin treatment did not decrease T-lymphocyte or monocyte activation, circulating biomarker levels (interleukin-6, D-dimer, soluble CD14, soluble CD163, monocyte chemoattractant protein-1, interferon-gamma–induced protein-10, high-sensitivity C-reactive protein, CD40L, and P-selectin) or white blood cell Krüppel-like Factor 2/4 messenger RNA levels. Pre-to-post atorvastatin reductions in calculated LDL (−38%), oxidized-LDL (−33%), and lipoprotein-associated phospholipase A2 (−31%) were significant (P < .01). In virologically suppressed individuals with HIV infection, atorvastatin did not significantly decrease levels of soluble or cellular biomarkers of immune activation and inflammation but resulted in robust reductions in LDL cholesterol, oxLDL, and lipoprotein-associated phospholipase A2, biomarkers associated with cardiovascular risk." @default.
• W2528418626 created "2016-10-14" @default.
• W2528418626 creator A5000175141 @default.
• W2528418626 creator A5005994764 @default.
• W2528418626 creator A5007661447 @default.
• W2528418626 creator A5011829870 @default.
• W2528418626 creator A5019429067 @default.
• W2528418626 creator A5020870466 @default.
• W2528418626 creator A5023967411 @default.
• W2528418626 creator A5025377609 @default.
• W2528418626 creator A5027387717 @default.
• W2528418626 creator A5029030800 @default.
• W2528418626 creator A5035764371 @default.
• W2528418626 creator A5035906293 @default.
• W2528418626 creator A5041002118 @default.
• W2528418626 creator A5045990611 @default.
• W2528418626 creator A5054820746 @default.
• W2528418626 creator A5063298724 @default.
• W2528418626 creator A5064663288 @default.
• W2528418626 creator A5072899489 @default.
• W2528418626 creator A5085282020 @default.
• W2528418626 creator A5088973456 @default.
• W2528418626 date "2017-01-01" @default.
• W2528418626 modified "2023-10-18" @default.
• W2528418626 title "Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1–infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275)" @default.
• W2528418626 cites W1497170016 @default.
• W2528418626 cites W1709407542 @default.
• W2528418626 cites W1969836247 @default.
• W2528418626 cites W1975953426 @default.
• W2528418626 cites W1997965169 @default.
• W2528418626 cites W2001231188 @default.
• W2528418626 cites W2007378793 @default.
• W2528418626 cites W2010296225 @default.
• W2528418626 cites W2026616659 @default.
• W2528418626 cites W2042693064 @default.
• W2528418626 cites W2049539466 @default.
• W2528418626 cites W2050125360 @default.
• W2528418626 cites W2054473991 @default.
• W2528418626 cites W2055303465 @default.
• W2528418626 cites W2067638840 @default.
• W2528418626 cites W2072302043 @default.
• W2528418626 cites W2083533606 @default.
• W2528418626 cites W2090055160 @default.
• W2528418626 cites W2101207877 @default.
• W2528418626 cites W2122483069 @default.
• W2528418626 cites W2129789761 @default.
• W2528418626 cites W2130603879 @default.
• W2528418626 cites W2131385716 @default.
• W2528418626 cites W2137983259 @default.
• W2528418626 cites W2141449346 @default.
• W2528418626 cites W2142283630 @default.
• W2528418626 cites W2148314152 @default.
• W2528418626 cites W2150031599 @default.
• W2528418626 cites W2150050151 @default.
• W2528418626 cites W2153136696 @default.
• W2528418626 cites W2153777696 @default.
• W2528418626 cites W2162249283 @default.
• W2528418626 cites W2162654321 @default.
• W2528418626 cites W2167056324 @default.
• W2528418626 cites W2315744235 @default.
• W2528418626 cites W2392201426 @default.
• W2528418626 cites W2401325207 @default.
• W2528418626 cites W2402331083 @default.
• W2528418626 cites W2434245634 @default.
• W2528418626 cites W75070731 @default.
• W2528418626 doi "https://doi.org/10.1016/j.jacl.2016.09.017" @default.
• W2528418626 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5407297" @default.
• W2528418626 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28391912" @default.
• W2528418626 hasPublicationYear "2017" @default.
• W2528418626 type Work @default.
• W2528418626 sameAs 2528418626 @default.
• W2528418626 citedByCount "28" @default.
• W2528418626 countsByYear W25284186262018 @default.
• W2528418626 countsByYear W25284186262019 @default.
• W2528418626 countsByYear W25284186262020 @default.
• W2528418626 countsByYear W25284186262021 @default.
• W2528418626 countsByYear W25284186262022 @default.
• W2528418626 countsByYear W25284186262023 @default.
• W2528418626 crossrefType "journal-article" @default.
• W2528418626 hasAuthorship W2528418626A5000175141 @default.
• W2528418626 hasAuthorship W2528418626A5005994764 @default.
• W2528418626 hasAuthorship W2528418626A5007661447 @default.
• W2528418626 hasAuthorship W2528418626A5011829870 @default.
• W2528418626 hasAuthorship W2528418626A5019429067 @default.
• W2528418626 hasAuthorship W2528418626A5020870466 @default.
• W2528418626 hasAuthorship W2528418626A5023967411 @default.
• W2528418626 hasAuthorship W2528418626A5025377609 @default.
• W2528418626 hasAuthorship W2528418626A5027387717 @default.
• W2528418626 hasAuthorship W2528418626A5029030800 @default.
• W2528418626 hasAuthorship W2528418626A5035764371 @default.
• W2528418626 hasAuthorship W2528418626A5035906293 @default.
• W2528418626 hasAuthorship W2528418626A5041002118 @default.
• W2528418626 hasAuthorship W2528418626A5045990611 @default.
• W2528418626 hasAuthorship W2528418626A5054820746 @default.
• W2528418626 hasAuthorship W2528418626A5063298724 @default.
• W2528418626 hasAuthorship W2528418626A5064663288 @default.
• W2528418626 hasAuthorship W2528418626A5072899489 @default.
• W2528418626 hasAuthorship W2528418626A5085282020 @default.

• next